natgillin/translations-raw huggingface dataset:
Et cross-over studie hos 40 raske forsøgspersoner, 10 i hver af de fire CYP2C19-metaboliske grupper (ultrahurtig, udtalt, moderat eller ringe), evaluerede farmakokinetisk og trombocythæmmende respons ved anvendelse af 300 mg efterfulgt af 75 mg/dag og 600 mg efterfulgt af 150 mg/dag, hver for i alt 5 dage (steady state).
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
Potente og moderate CYP2C19-hæmmere inkluderer for eksempel omeprazol og esomeprazol, fluvoxamin, fluoxetin, moclobemid, voriconazol, fluconazol, ticlopidin, carbamazepin og efavirenz.
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz.
80 mg omeprazol en gang daglig administreret enten samtidigt med clopidogrel eller med 12 timers mellemrum nedsatte eksponeringen for den aktive metabolit med 45 % (ved initial mætningsdosis) og 40 % (vedligeholdelsesdosis).
Omeprazole 80 mg once daily administered either at the same time as clopidogrel or with 12 hours between the administrations of the two drugs decreased the exposure of the active metabolite by 45% (loading dose) and 40% (maintenance dose).
En farmakodynamisk interaktion mellem Clopidogrel/Acetylsalicylic acid Mylan og heparin er mulig, hvilket kan medføre øget blødningsrisiko.
A pharmacodynamic interaction between Clopidogrel/Acetylsalicylic acid Mylan and heparin is possible, leading to increased risk of bleeding.
Den aktive tiolmetabolit, som er blevet isoleret in vitro, binder hurtigt og irreversibelt til trombocytreceptorerne, hvorved trombocytaggregationen hæmmes.
The active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation.
I nogle enkelte tilfælde er der indberettet blødning i øjne, i hoved (særligt hos ældre), lunger eller led.
In a small number of cases, bleeding in the eye, inside the head (especially in elderly), the lung or the joints has also been reported.
Muskuloskeletal blødning (hæmartrose), artrit, artralgi, myalgi.
Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
Samtidig administration af salicylater og valproinsyre kan medføre nedsat proteinbinding af valproinsyre og hæmme metaboliseringen af valproinsyre, hvilket medfører øget serumkoncentration af total og fri valproinsyre.
The concomitant administration of salicylates and valproic acid may result in decreased valproic acid protein binding and inhibition of valproic acid metabolism resulting in increased serum levels of total and free valproic acid.
På grund af risikoen for blødninger og hæmatologiske bivirkninger bør det med det samme overvejes at kontrollere blodstatus og/eller foretage andre passende prøver, hvis der i løbet af behandlingen opstår kliniske symptomer, der tyder på blødning (se pkt.
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8).
Clopidogrel/Acetylsalicylic acid Mylan kan ikke anbefales til denne population.
Clopidogrel/Acetylsalicylic acid Mylan is not recommended in this population.
Croscarmellosenatrium Hydroxypropylcellulose Silica, kolloid vandfri Talkum
Croscarmellose sodium Hydroxypropylcellulose Colloidal anhydrous silica Talc
Der er også påvist interaktioner med de følgende lægemidler med højere doser af ASA: angiotensin converting enzyme (ACE)-hæmmere, fenytoin, betablokkere, diuretika og orale hyperglykæmika.
Interactions with the following medicinal products with higher (anti-inflammatory) doses of ASA have also been reported: angiotensin converting enzyme (ACE) inhibitors, phenytoin, beta blockers, diuretics, and oral hypoglycemic agents.
Clopidogrel/Acetylsalicylic acid Mylan indeholder natrium Denne medicin indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. den er i det væsentlige 'natriumfri'.
Clopidogrel/Acetylsalicylic acid Mylan contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree'.
Følgende symptomer er forbundet med forgiftning: svimmelhed, hovedpine, tinnitus, konfusion og gastrointestinale symptomer (kvalme, opkastning og gastriske smerter).
The following symptoms are associated with moderate intoxication: dizziness, headache, tinnitus, confusion and gastrointestinal symptoms (nausea, vomiting and gastric pain).
Doser på 500 mg/dag og derover:
Doses of 500 mg/day and above:
Der blev ikke observeret nogen betydende forskelle i eksponering for den aktive metabolit og gennemsnitlig hæmning af trombocytfunktionen (IPA) mellem personer med ultrahurtig, udtalt eller moderat metabolisme.
No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultra-rapid, extensive and intermediate metabolisers.
Hyppigheden af klinisk signifikant blødning lignede den, der ses, når trombolytiske midler og heparin indgives samtidig med ASA (se pkt.
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8).
- Hvis du får smerter i maveregionen eller blødning i mave eller tarme (rød eller sort afføring).
if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red stools or black stools).
Herudover blev clopidogrels farmakodynamiske aktivitet ikke påvirket signifikant af samtidig administration af phenobarbital, cimetidin eller østrogen.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the co-administration of phenobarbital or oestrogen.
Indehaveren af markedsføringstilladelsen skal fremsende periodiske, opdaterede sikkerhedsindberetninger for dette lægemiddel i overensstemmelse med kravene på listen over EUreferencedatoer (EURD list), som fastsat i artikel 107c, stk. 7, i direktiv 2001/83/EF og offentliggjort på det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Non-kardiogent lungeødem kan forekomme ved akut og kronisk overdosering med acetylsalicylsyre (se pkt.
Non-cardiogenic pulmonary edema can occur with acute and chronic acetylsalicylic acid overdose (see section 4.8).
Det primære endepunkt (den kombinerede forekomst af kardiovaskulær død, myokardieinfarkt, apopleksi eller BARC (Bleeding Academic Research Consortium) blødning ≥ 2 ved 12 måneder) blev nået med visning af non-inferioritet.
The primary endpoint (the combined incidence of CV death, MI, stroke and BARC bleeding grade ≥2 at 12 months) was met showing non-inferiority.
Advarsler og forsigtighedsregler Hvis nogen af følgende situationer gælder for dig, skal du oplyse det til lægen, før du tager Clopidogrel/Acetylsalicylic acid Mylan:
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel/Acetylsalicylic acid Mylan:
Clopidogrel/Acetylsalicylic acid Mylan fast dosiskombination anvendes efter indledning af behandling med clopidogrel og ASA givet separat, og erstatter de individuelle clopidogrel og ASA produkter.
Clopidogrel/Acetylsalicylic acid Mylan fixed-dose combination is used following initiation of therapy with clopidogrel and ASA given separately and replaces the individual clopidogrel and ASA products.
Efterfølgende metabolisering af 2-oxo-clopidogrel-metabolitten resulterer i dannelsen af den aktive metabolit, et tiolderivat af clopidogrel.
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.
• hvis du drikker alkohol, da der er en øget risiko for blødning i eller skader på mave-tarmkanalen.
• if you drink alcohol, because of the increased risk of bleeding or gastrointestinal injury.
Glykoprotein (GP)IIb/IIIa-hæmmere
Glycoprotein IIb/IIIa inhibitors
Farmakogenetik: Hos patienter med nedsat CYP2C19-metabolisme omdannes en mindre del af den anbefalede dosis af clopidogrel til den aktive metabolit og har derfor en mindre effekt på trombocytfunktionen.
Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel and has a smaller effect on platelet function.
Intrakraniel blødning (nogle med dødelig udgang, især hos ældre), hovedpine, paræstesier, svimmelhed
Intracranial bleeding (some cases were reported with fatal outcome, especially in elderly), headache, paraesthesia, dizziness
• Akut myokardieinfarkt med elevation af ST-segmentet hos medicinsk behandlede patienter, der er egnede til trombolytisk behandling
• ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy
Clopidogrels aktive metabolit hæmmer selektivt bindingen af adenosindiphosphat (ADP) til dets trombocyt P2Y12-receptor og den efterfølgende ADP-medierede aktivering af glykoprotein (GP)IIb- IIIa-komplekset, hvorved trombocytaggregationen hæmmes.
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Colitis (inklusive colitis ulcerosa og lymfocytisk colitis), stomatitis, akut pankreatitis i forbindelse med en overfølsomhedsreaktion på grund af acetylsalicylsyre
Colitis (including ulcerative or lymphocytic colitis), stomatitis, acute pancreatitis in the context of a hypersensitivity reaction due to acetylsalicylic acid*
• valproinsyre, valproat eller carbamazepin, medicin til behandling af bestemte typer epilepsi,
• valproic acid, valproate or carbamazepine, medicines to treat some forms of epilepsy,
Det primære resultat sammensat af kardiovaskulær død, slagtilfælde, akut revaskularisering og BARC (Bleeding Academic Research Consortium) blødning ≥ 2 ved 1-år efter ACS, forekom hos 43 patienter (13,4 %) i de-eskaleret DAPT gruppen og hos 85 patienter (26,3 %) i den uændrede DAPT-gruppe (p < 0,01).
The primary outcome, a composite of cardiovascular death, stroke, urgent revascularization, and BARC (Bleeding Academic Research Consortium) bleeding ≥2 at 1 year post ACS, occurred in 43 patients (13.4%) in the de-escalated DAPT group and in 85 patients (26.3%) in the unchanged DAPT group (p<0.01).
Metaboliske og ernæringsmæssige lidelser
Metabolism and nutrition disorders
Du må ikke tage Clopidogrel/Acetylsalicylic acid Mylan under graviditetens tredje trimester.
Do not take Clopidogrel/Acetylsalicylic acid Mylan during third trimester of pregnancy.
Alvorlig blødning, blødning i operationssår, vaskulitis (inklusive Henoch-Schönlein purpura
Serious haemorrhage, haemorrhage of operative wound, vasculitis (including Henoch-Schönlein purpura*), hypotension
Der findes ingen fertilitetsdata for clopidogrel/acetylsalicylsyre.
There are no fertility data with clopidogrel/acetylsalicylic acid.
Blødninger defineret som BARC forekom hos 30 patienter (9,3 %) i de-eskaleret DAPT gruppen og hos 76 patienter (23,5 %) i den uændrede DAPT gruppe (p < 0,01).
Bleeding events defined as all BARC occurred in 30 patients (9.3%) in the deescalated DAPT group and in 76 patients (23.5%) in the unchanged DAPT group (p<0.01).
*, akut nyreinsufficiens (særligt hos patienter med eksisterende nedsat nyrefunktion, kardial dekompensation, nefrotisk syndrom eller samtidig behandling med diuretika) glomerulonefrit, forhøjet blodkreatinin
Renal failure*, acute renal impairment (especially in patients with existing renal impairment, heart decompensation, nephritic syndrome, or concomitant treatment with diuretics) *, glomerulonephritis, blood creatinine increased
Da SSRI'er påvirker trombocytaktiveringen og øger risikoen for blødning, skal der udvises forsigtighed ved samtidig administration af SSRI'er og clopidogrel.
Since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution.
15,0 % af patienterne i clopidogrel plus ASA-gruppen og 21,7 % i gruppen behandlet med ASA alene opnåede det primære endepunkt, hvilket viste en absolut reduktion på 6,7 % og en odds-reduktion på 36 % til fordel for clopidogrel (95 % CI: 24; 47 %; p <0,001), der hovedsageligt var relateret til en reduktion af infarkt-relaterede okkluderede arterier.
Fifteen percent (15.0%) of patients in the clopidogrel plus ASA group and 21.7% in the group treated with ASA alone reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favour of clopidogrel (95% CI: 24, 47%; p <0.001), mainly related to a reduction in occluded infarct-related arteries.
• bliver vaccineret mod skoldkopper eller helvedesild indenfor 6 uger efter brug af Clopidogrel/Acetylsalicylic acid Mylan, eller hvis du har/får skoldkopper eller helvedsild (se afsnit 2 ”Børn og unge”),
• the varicella vaccine, a medicine used to prevent chickenpox or shingles, within 6 weeks of taking Clopidogrel/Acetylsalicylic acid Mylan, or if you have active chickenpox or shingles infection (see section 2 ‘Children and adolescents'),
Sjældne bivirkninger (kan påvirke op til 1 ud af 1.000 patienter): Svimmelhed (fornemmelse af at snurre rundt), forstørrede bryster hos mænd.
Rare side effect (may affect up to 1 in 1000 people): Vertigo, enlarged breasts in males.
COMMIT-studiet, som var designet med 2×2 faktorer, inkluderede 45.852 patienter, der var til rådighed inden for 24 timer efter indtrådte symptomer, som var mistænkt for at være MI, og hvor EKG-anomalier (dvs. ST-elevation, ST-depression eller venstresidig grenblok) understøttede dette.
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST
Polyvinylalkohol (delvist hydrolyseret) Titandioxid (E171)
Poly (vinyl alcohol) (partially hydrolysed) Titanium dioxide (E171)
CURE-undersøgelsen omfattede 12.562 patienter med akut koronarsyndrom uden forhøjelse af STsegmentet (ustabil angina pectoris eller myokardieinfarkt uden forekomst af Q-takker), som indfandt sig inden for 24 timer efter starten på den seneste episode med brystsmerter eller symptomer, der svarede til iskæmi.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Lægen bør fortsat være opmærksom på tegn på GI-ulceration og blødning, også hvis patienten ikke tidligere har haft gastrointestinale symptomer.
Physicians should remain alert for signs of GI ulceration and bleeding, even in the absence of previous GI symptoms.
Lidelser i immunsystemet
Immune system disorders
Forekomsten af større blødninger var ens i de to grupper.
The incidence of major bleeding was similar between groups.
Clopidogrel metaboliseres først til en 2-oxo-clopidogrel-metabolit.
Clopidogrel is first metabolised to a 2-oxo-clopidogrel intermediate metabolite.
Hydrogeneret ricinusolie Stivelse, pregelatineret Stearinsyre
Hydrogenated castor oil Starch pregelatinized Stearic acid
Clopidogrel/Acetylsalicylic acid Mylan er indiceret til sekundær forebyggelse af aterotrombotiske hændelser hos voksne patienter, der allerede tager både clopidogrel og acetylsalicylsyre (ASA).
Clopidogrel/Acetylsalicylic acid Mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).
I CLARITY var der en generel stigning i antallet af blødninger i clopidogrel plus ASA-gruppen versus ASA-gruppen.
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the group taking ASA alone.
Du har fået ordineret Clopidogrel/Acetylsalicylic acid Mylan i stedet for de to indholdsstoffer clopidogrel og acetylsalicylsyre enkeltvist for at forebygge blodpropper, fordi du har haft en alvorlig form for smerter i brystet (ustabil angina pectoris) eller et hjerteanfald (myokardieinfarkt).
You have been prescribed Clopidogrel/Acetylsalicylic acid Mylan in place of the two separate medicines, clopidogrel and ASA, to help prevent blood clots because you have experienced a severe type of chest pain known as ‘unstable angina' or heart attack (myocardial infarction).
Hvis du har taget for meget Clopidogrel/Acetylsalicylic acid Mylan Kontakt din læge eller tag på den nærmeste skadestue på grund af den øgede blødningsrisiko.
If you take more Clopidogrel/Acetylsalicylic acid Mylan than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Flere end 30.000 patienter, som indgik i kliniske studier med clopidogrel plus ASA ved vedligeholdelsesdoser på 325 mg eller lavere, fik en lang række ledsagende lægemidler såsom diuretika, betablokkere, ACE-hæmmere, calciumantagonister, kolesterolsænkende midler, vasodilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa-hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
More than 30,000 patients entered into clinical trials with clopidogrel plus ASA at maintenance doses lower than or equal to 325 mg, and received a variety of concomitant medicinal products including diuretics, beta blockers, ACE Inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Efter absorption bliver ASA i Clopidogrel/Acetylsalicylic acid Mylan hydrolyseret til salicylsyre med peak-plasmakoncentration af salicylsyre inden for 1 time efter dosering, sådan at plasmaniveauet af ASA er så godt som udetekterbart 1,5-3 timer efter dosering.
Following absorption, the ASA in Clopidogrel/Acetylsalicylic acid Mylan is hydrolysed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing.
Salicylsyren i Clopidogrel/Acetylsalicylic acid Mylan har en plasmahalveringstid på ca. 2 timer.
Salicylic acid in Clopidogrel/Acetylsalicylic acid Mylan has a plasma half-life of approximately 2 hours.
Sikkerheden og virkningen af clopidogrel plus ASA er blevet evalueret i 3 dobbeltblindede studier, der omfattede mere end 61.900 patienter i CURE-, CLARITY- og COMMIT-undersøgelserne, hvor clopidogrel plus ASA sammenlignes med ASA alene.
The safety and efficacy of clopidogrel plus ASA have been evaluated in three double-blind studies involving over 61,900 patients: the CURE, CLARITY and COMMIT studies, comparing clopidogrel plus ASA to ASA alone, both treatments given in combination with other standard therapy.
Eksperimentelle data tyder på, at ibuprofen kan hæmme effekten af lave doser acetylsalicylsyre på trombocytaggregation ved samtidig administration.
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly.
ASA i Clopidogrel/Acetylsalicylic acid Mylan hydrolyseres hurtigt i plasma til salicylsyre, med en halveringstid på 0,3 til 0,4 timer for ASA-doser fra 75 - 100 mg. Salicylsyre konjugeres primært i leveren og danner salicylsyre, et fenolglukuronid, et acylglukuronid og et antal underordnede metabolitter.
The ASA in Clopidogrel/Acetylsalicylic acid Mylan is rapidly hydrolysed in plasma to salicylic acid, with a half-life of 0.3 to 0.4 hours for ASA doses from 75 to 100 mg. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
Ud fra din sygdom vil lægen bestemme, hvor lang tid du skal tage Clopidogrel/Acetylsalicylic acid Mylan.
Depending on your condition, your doctor will determine the length of time for which you need to take Clopidogrel/Acetylsalicylic acid Mylan.
Kounis syndrom (vasospastisk allergisk angina/allergisk myokardieinfarkt) i forbindelse med en allergisk reaktion på grund af acetylsalicylsyre eller clopidogrel
Kounis syndrome (vasospastic allergic angina / allergic myocardial infarction) in the context of a hypersensitivity reaction due to acetylsalicylic acid* or clopidogrel**
Hvis du bliver gravid, mens du tager Clopidogrel/Acetylsalicylic acid Mylan, skal du omgående kontakte din læge, da det frarådes at tage Clopidogrel/Acetylsalicylic acid Mylan under graviditet.
If you become pregnant while taking Clopidogrel/Acetylsalicylic acid Mylan, consult your doctor immediately as it is recommended not to take Clopidogrel/Acetylsalicylic acid Mylan while you are pregnant.
• probenecid, benzbromaron eller sulfinpyrazon, lægemidler til behandling af urinsur gigt,
• probenecid, benzbromarone, or sulfinpyrazone, medicines used to treat gout,
• fluconazol eller voriconazol, der anvendes til behandling af svampeinfektioner,
• fluconazole or voriconazole, medicines to treat fungal infections,
Bulløs dermatitis (toksisk epidermal nekrolyse, StevensJohnsons syndrom, erythema multiforme, akut generaliseret eksantematøs pustulose (AGEP)), angioødem, lægemiddelinduceret overfølsomhed, medikamentelt udslæt med eosinofili og systemiske symptomer (DRESS), erytematøst eller eksfoliativt udslæt, urticaria, eksem, lichen planus, fixed drug eruption
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, druginduced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus, fixed eruption*
Farmakokinetikken og den antitrombotiske effekt, målt ved ex vivo trombocytaggregationsundersøgelse, adskiller sig alt efter CYP2C19-genotype.
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
• repaglinid, medicin til behandling af sukkersyge (diabetes),
• repaglinide, medicine to treat diabetes,
• hvis du lider af en alvorlig leversygdom.
• if you suffer from severe liver disease.
Gulsot (gulfarvning af hud og/eller øjne); brændende fornemmelse i maven og/eller spiserøret; alvorlige mavesmerter med eller uden rygsmerter; feber, åndedrætsbesvær indimellem ledsaget af hoste; generelle allergiske reaktioner (f.eks. varmefølelse over hele kroppen med pludselig almen utilpashed og eventuelt besvimelse); hævelse i munden; blærer på huden; allergiske hudreaktioner; ømhed i munden (stomatitis); blodtryksfald; forvirring; hallucinationer; ledsmerter; muskelsmerter; smagsforstyrrelser eller mangel på smagssans, betændelse i små kar.
Jaundice (yellowing of skin and/or eyes); burning in stomach and/or oesophagus (gullet); severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of foods, inflammation of small vessels.
28 filmovertrukne tabletter 30 filmovertrukne tabletter
28 film-coated tablets 30 film-coated tablets